Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The revision label was updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:54:18.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria are indicated.
    Difference
    0.1%
    Check dated 2026-02-04T23:34:02.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option, introduced the label 'Last Update Submitted that Met QC Criteria' (changing from 'Last Update Submitted that met QC Criteria'), and adjusted capitalization for 'No FEAR Act Data'. The site revision was updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T22:18:46.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Administrative updates to the study page include new 2026 update dates and the removal of an older regulatory note; these are updates to page metadata rather than the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-01-21T18:10:56.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Minor update: revision label changed from v3.3.3 to v3.3.4; no study content or functionality was changed.
    Difference
    0.1%
    Check dated 2026-01-14T07:37:15.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Adds Minnesota as a Location under the Locations section (revision v3.3.3) and removes the HHS Vulnerability Disclosure and Minnesota Locations entries (revision v3.3.2).
    Difference
    0.2%
    Check dated 2025-12-24T02:38:16.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.